Skip to main content

Table 1 Patient characteristics for pT1/T2, N0

From: The risk factors of local recurrence and distant metastasis on pT1/T2N0 mid-low rectal cancer after total mesorectal excision

Variable

279 patients (% or [Q1 − Q3] †)

No recurrence (n=260, %)

Recurrence (n=19, %)

Age

63.8± 12.4

58.4 ± 11.0

BMI (kg/m2)

24.1± 3.2

24.8 ± 3.4

Male gender

141 (54.2)

12 (63.2)

Family cancer history

79 (30.4)

8 (42.1)

Preoperative CEA (ng/mL)

1.8 [1.1–2.7]

2.3 [1.5–6.7]

Preoperative CEA ≥ 5*

30 (11.5)

7 (36.8)

Preoperative hemoglobin (g/dL)

12.8 ± 2.0

13.8 ± 1.8

Preoperative albumin (g/dL)

4.23 ± 0.40

4.32 ± 0.37

Distance from anal verge (cm)*

5.9 ± 1.7

4.9 ± 1.9

 Distance from anal verge ≤ 5

108 (41.5)

12 (63.2)

Operation type

 Low anterior resection

241 (92.7)

17 (89.5)

 Abdomino-perineal resection

17 (6.5)

2 (10.5)

 Hartmann’s procedure

2 (0.8)

0

Neo-adjuvant radiotherapy

41 (15.8)

6 (31.6)

Adjuvant therapy

4 (1.5)

0

 Chemotherapy

3 (1.2)

0

 CRT

1 (0.4)

0

PeriOP colostomy/ileostomy

149 (57.3)

15 (78.9)

PostOP complication/morbidity

68 (26.2)

3 (15.8)

 Early

43 (16.5)

3 (15.8)

 Late

37 (14.2)

1 (5.3)

Resection margin (cm)

1.5 [0.8–2.2]

0.8 [0.5–1.7]

Resection margin < 0.9 *

78 (30.0)

10 (52.6)

Resection margin < 1.4 *

118 (45.4)

14 (73.7)

Tumor diameter (cm)

3.0 ± 1.4

3.3 ± 1.1

 Tumor diameter ≥ 2.7

137 (52.7)

13 (72.2)

T stage

 T1

98 (37.7)

5 (26.3)

 T2

162 (62.3)

14 (73.7)

Lymph node yield

20 [14–28]

16 [11–33]

Lymph node yield ≥ 14*

207 (79.6)

11 (57.9)

Lymphovascular invasion

12 (4.6)

1 (5.3)

Perineural invasion

13 (5.0)

0

Differentiation

 Poor

4 (1.5)

1 (5.3)

 Moderate

195 (75.0)

15 (78.9)

 Well

61 (23.5)

3 (15.8)

Follow-up (month)

73.5 [48–108]

 

 Total follow-up length

79.6 [51–109]

64.9 [54–102]

 Time to local recurrence

 

25.6 [13.7–38.8]

 Time to distant metastasis

 

31.4 [12.9–59.2]

  1. BMI body mass index, CEA carcinoembryonic antigen, CRT chemoradiotherapy
  2. *p value < 0.05
  3. Median [25 percentile–75 percentile]
  4. Short-course radiotherapy 500cGy*5days